Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies.

Cai D, Qin J, Chen G, Feng W, Liu J.

Minerva Med. 2017 Oct;108(5):464-472. doi: 10.23736/S0026-4806.17.05055-8. Epub 2017 May 2. Review.

PMID:
28466630
2.

A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy.

Kunisaki C, Tanaka Y, Kosaka T, Miyamoto H, Sato S, Suematsu H, Yukawa N, Sato K, Izumisawa Y, Akiyama H, Taguri M, Yamanaka T, Endo I.

Digestion. 2017;95(2):162-171. doi: 10.1159/000458755. Epub 2017 Feb 18.

PMID:
28214864
3.

The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.

Busby J, Murchie P, Murray L, Iversen L, Lee AJ, Spence A, Watson MC, Cardwell CR.

Int J Cancer. 2017 Apr 15;140(8):1828-1835. doi: 10.1002/ijc.30612. Epub 2017 Feb 6.

PMID:
28120338
4.

Platinum-zoledronate complex blocks gastric cancer cell proliferation by inducing cell cycle arrest and apoptosis.

Yang H, Qiu L, Zhang L, Lv G, Li K, Yu H, Xie M, Lin J.

Tumour Biol. 2016 Aug;37(8):10981-92. doi: 10.1007/s13277-016-4977-2. Epub 2016 Feb 19.

PMID:
26891667
5.

Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.

Wright E, Schofield PT, Molokhia M.

BMJ Open. 2015 Dec 7;5(12):e007133. doi: 10.1136/bmjopen-2014-007133. Review.

6.

The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.

Chen LX, Ning GZ, Zhou ZR, Li YL, Zhang D, Wu QL, Zhang TS, Cheng L, Feng SQ.

PLoS One. 2015 Apr 16;10(4):e0123080. doi: 10.1371/journal.pone.0123080. eCollection 2015. Review.

7.

Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.

Cappetta A, Spano L, Evangelista L, Zovato S, Opocher G, Pastorelli D.

Anticancer Drugs. 2015 Feb;26(2):232-5. doi: 10.1097/CAD.0000000000000169.

PMID:
25243456
8.

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K.

Cancer Med. 2014 Apr;3(2):362-75. doi: 10.1002/cam4.196. Epub 2014 Feb 7.

9.

A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway.

Wang HJ, Liu Y, Fan LQ, Han CL, Jiang Y, Cheng SJ, Li Y.

Acta Pharmacol Sin. 2013 Dec;34(12):1535-44. doi: 10.1038/aps.2013.103. Epub 2013 Nov 18.

10.

Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.

Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, Santini D.

PLoS One. 2013 Oct 28;8(10):e74402. doi: 10.1371/journal.pone.0074402. eCollection 2013.

11.

99mTc-MDP uptake in implantation metastasis of gastric cancer: the additional value of SPECT/CT.

Zhao H, Han J, Lv F, Zhang C.

Clin Nucl Med. 2013 Oct;38(10):838-40. doi: 10.1097/RLU.0b013e3182a43089.

PMID:
24107817
12.
13.

Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).

Wright E, Schofield PT, Seed P, Molokhia M.

PLoS One. 2012;7(10):e47616. doi: 10.1371/journal.pone.0047616. Epub 2012 Oct 24.

14.

Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.

Weinreich J, Schott TC, Königsrainer I, Küper M, Königsrainer A, Schott H.

Anticancer Res. 2012 Oct;32(10):4299-305.

PMID:
23060550
15.

Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.

Lim JS, Jin SH, Kim SB, Lee JI.

J Clin Gastroenterol. 2012 Sep;46(8):669-74. doi: 10.1097/MCG.0b013e31824f1af4.

PMID:
22504799
16.

Esophageal and gastric cancer incidence and mortality in alendronate users.

Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R.

J Bone Miner Res. 2012 Mar;27(3):679-86. doi: 10.1002/jbmr.1481.

17.
18.

Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.

Yamasaki A, Onishi H, Morisaki T, Katano M.

Anticancer Res. 2011 Jul;31(7):2419-24.

PMID:
21873153
19.
20.

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.

Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V.

BMJ. 2010 Sep 1;341:c4444. doi: 10.1136/bmj.c4444.

Supplemental Content

Loading ...
Support Center